Literature DB >> 26422398

A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.

Anne Lynn S Chang1, Jinah Kim2, Richard Luciano3, Loretta Sullivan-Chang3, Alexander D Colevas3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26422398     DOI： 10.1001/jamadermatol.2015.2705

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  19 in total

1.  Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma.

Authors:  Angela Steineck; Niklas Krumm; Jay F Sarthy; Colin C Pritchard; Teresa Chapman; Andrew W Stacey; Nicholas A Vitanza; Bonnie Cole
Journal:  JCO Precis Oncol       Date:  2019-09-20

2.  Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck.

Authors:  Samantha Tam; Christopher M K L Yao; Moran Amit; Mona Gajera; Xiaoning Luo; Rachel Treistman; Anshu Khanna; Mohamed Aashiq; Priyadharsini Nagarajan; Diana Bell; Adel El-Naggar; Michael Migden; Michael Wong; Bonnie Glisson; Renata Ferrarotto; Bita Esmaeli; David Rosenthal; Guojun Li; Randal S Weber; Jeffrey N Myers; Neil D Gross
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-02-01       Impact factor: 6.223

Review 3.  Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.

Authors:  Dai Ogata; Tetsuya Tsuchida
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

Review 4.  [Cutaneous squamous cell carcinoma].

Authors:  U Leiter; R Gutzmer; M Alter; C Ulrich; A S Lonsdorf; M M Sachse; U Hillen
Journal:  Hautarzt       Date:  2016-11       Impact factor: 0.751

Review 5.  Management of High-Risk Squamous Cell Carcinoma of the Skin.

Authors:  Teresa Fu; Sumaira Z Aasi; S Tyler Hollmig
Journal:  Curr Treat Options Oncol       Date:  2016-07

6.  Unresectable cutaneous squamous cell carcinoma of the forehead with MLH1 mutation showing dramatic response to Programmed Cell Death Protein 1 Inhibitor Therapy.

Authors:  Jed H Assam; Steven Powell; William C Spanos
Journal:  Clin Skin Cancer       Date:  2016-11-23

7.  Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma.

Authors:  Amit Mittal; Mike Wang; Aurobind Vidyarthi; Diana Yanez; Gabriela Pizzurro; Durga Thakral; Erin Tracy; Oscar R Colegio
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.996

Review 8.  Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies.

Authors:  Priscila Oliveira de Lima; Shannon Joseph; Benedict Panizza; Fiona Simpson
Journal:  Curr Treat Options Oncol       Date:  2020-02-03

Review 9.  Immune checkpoint inhibitors to treat cutaneous malignancies.

Authors:  Dulce M Barrios; Mytrang H Do; Gregory S Phillips; Michael A Postow; Tomoko Akaike; Paul Nghiem; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2020-05-24       Impact factor: 11.527

Review 10.  Investigative Landscape in Advanced Non-Melanoma Skin Cancers.

Authors:  Priyanka Reddy; Min Yao; Monaliben Patel
Journal:  Curr Treat Options Oncol       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.